Form 8-K - Current report:
SEC Accession No. 0001641172-25-014905
Filing Date
2025-06-12
Accepted
2025-06-12 17:05:28
Documents
13
Period of Report
2025-06-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 52710
2 EX-99.1 ex99-1.htm EX-99.1 60384
  Complete submission text file 0001641172-25-014905.txt   294504

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE kapa-20250610.xsd EX-101.SCH 3026
4 XBRL LABEL FILE kapa-20250610_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE kapa-20250610_pre.xml EX-101.PRE 22366
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3801
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42275 | Film No.: 251043771
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)